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ABSTRACT
Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy worldwide and is 
the leading cause of death in patients with cirrhosis. In early-stage tumors, potential curative therapies have 
been used including ablative therapies using percutaneous ethanol injection (PEI), percutaneous acetic acid 
injection (PAI) or radiofrequency ablation (RFA); surgical resection and liver transplantation. RFA is more 
effective and safer than other local ablative therapy modalities. RFA should be considered as the first-line 
treatment for patients with small HCC, i.e. sized less than 5 cm; preferably less than or equal to 3 cm since they 
are not suitable for liver resection or liver transplantation. RFA should also be compared with transarterial 
embolization, which currently has been considered as the standard HCC therapy in some countries. It has been 
reported that the combination of RFA and embolization treatment may reduce the early and late recurrence rate. 
Keywords: hepatocellular carcinoma, percutaneous ethanol injection, acetic acid injection, radiofrequency 
ablation 
ABSTRAK
Karsinoma hepatoselular merupakan tumor ganas hati yang sering ditemukan di seluruh dunia dan 
merupakan penyebab tersering kematian pasien dengan sirosis hati. Pada fase awal kanker ini, beberapa 
modalitas tatalaksana telah digunakan, meliputi injeksi etanol perkutan, injeksi asam asetat perkutan atau ablasi 
radiofrekuensi; reseksi dan transplantasi hati. Ablasi radiofrekuensi merupakan modalitas ablasi yang paling 
efektif dan aman. Ablasi radiofrekuensi  merupakan pilihan pada kasus hepatoma dengan ukuran kurang dari 
5 cm, lebih dianjurkan ukuran yang lebih kecil atau sama dengan 3 cm, sepanjang reseksi maupun transplantasi 
hati tidak mungkin dilakukan. Ablasi radiofrekuensi sebaiknya dibandingkan dengan embolisasi transarterial 
dimana modalitas ini telah digunakan sebagai terapi standar untuk hepatoma di beberapa negara maju. 
Dilaporkan bahwa kombinasi ablasi radiofrekuensi dengan embolisasi transarterial dapat menurunkan angka 
kekambuhan.
Kata kunci: karsinoma hepatoselular, injeksi etanol perkutan, injeksi asam asetat, ablasi radiofrekuensi 
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most 
common primary hepatic malignancy worldwide 
and is the leading cause of death in patients with 
cirrhosis in Europe. Early detection strategies have 
increased the number of small HCC amenable to 
curative treatment.1
More than 600,000 people die of HCC each year. 
HCC is the sixth most common malignancy worldwide. 
It is the 5th most common malignant disease in male and 
the 8th most common in female. It is the 3rd most common 
cause of death from cancer, after lung and stomach 
cancer. HCC is the most common malignant disease 
in several regions of Africa and Asia. At least 300,000 
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prevalence of risk factors in the population, lack of 
medical expertise and facilities for early diagnosis, and 
lack of effective treatment following the diagnosis.2
BARCELONA CLINIC LIVER CANCER CLASSIFI-
CATION
The Barcelona clinic liver cancer classification 
(BCLC) is the most frequently utilized classification 
for management of HCC. In early-stage tumors, 
potential curative therapies have been used including 
ablative therapies using percutaneous ethanol injection 
(PEI), percutaneous acetic acid injection (PAI) or 
radiofrequency ablation (RFA); surgical resection 
and liver transplantation. Those treatments provide 
better survival rates at 5-years of 40–70% vs. < 20% 
for untreated patients; however, they are applicable in 
only 30–40% of patients with HCC.1
BCLC staging classification and treatment schedule 
consists of five staging: (1) Stage 0: patients with 
very early HCC are optimal candidates for resection; 
(2) Stage A: patients with early HCC are candidates 
for radical therapies (resection and ablation, liver 
transplantation or percutaneous treatments); (3) 
Stage B: patients with intermediate HCC may benefit 
from chemoembolization; (4) Stage C: patients with 
advanced HCC may receive new agents in the setting 
of a RCT; (5) Stage D: patients with end-stage disease 
will receive symptomatic treatment.5
SELECTING TREATMENT MODALITY 
Percutaneous treatments provide good results 
(5-year survival of 40–50%), but are unable to achieve 
response rates and outcomes comparable to those for 
surgical treatments, even when they are applied as 
the first option. Therefore, we consider percutaneous 
ablation as the best option for nonsurgical HCC. 
Percutaneous ethanol injection is easy to perform 
and obtains complete response rates in about 70% of 
solitary tumors less than 3 cm and in almost 100% 
in tumors less than 2 cm. Five-year survival in Child 
Turcotte Pugh (CTP) class A patients with small 
tumors may exceed 60%. Radiofrequency ablation 
has been claimed to require significantly less sessions 
than percutaneous ethanol injection to obtain the 
same response rates and is proposed to better control 
the local disease. Further RCTs are needed to confirm 
this statement. For sub-capsular tumors, percutaneous 
ethanol injection is preferred to radiofrequency 
ablation to prevent needle track seeding.5
Huo et al, compared PEI with PAI in a prospective 
study among cirrhotic patient. Sixty-three patients 
were treated by PAI using 50% acetic acid and 62 by 
of the 600,000 deaths worldwide occur in China alone, 
and the majority of the other 300,000 deaths occur in 
resource-challenged countries in sub-Saharan Africa. 
Worldwide research on the disease should be intensified 
in both medical and pharmaceutical fields, especially 
with a focus on providing help to areas where resources 
are limited. Treatment approaches depend on the stage 
of the disease at diagnosis and on access to complex 
treatment regimens. However, advanced disease is 
not curable, and management of advanced disease is 
expensive and only marginally effective in increasing 
quality-adjusted life years.2 
The incidence of HCC is increasing in Europe and 
the United States. It is currently the leading cause of 
death among cirrhotic patients. Chronic hepatitis B 
viral (HBV) infection is the predominant risk factor 
of HCC in Asia and Africa; while chronic hepatitis C 
viral (HCV) infection is the major cause of HCC in 
Western countries and Japan. Hepatocellular carcinoma 
develops in 80% cases of liver cirrhosis and such pre-
neoplastic condition is assumed to be the strongest 
predisposing factor. Chronic HBV carriers have a 
100-fold relative risk of developing HCC compared 
with non-carriers. The annual HCC incidence rate is 
2–6% in cirrhotic patients. Aflatoxin B1 intake further 
increases the risk of HCC. In Western countries and in 
Japan, HCV infection is the main risk factor for HCC, 
together with other causes of cirrhosis. Approximately 
20–30% of the estimated 170 million HCV-infected 
individuals worldwide will develop cirrhosis. Once 
cirrhosis is established, the annual incidence of HCC 
is of 3–5%, and one third of them will develop an HCC 
over their lifetime.3
CLINICAL PROBLEM 
HCC accounts for 80-90% of primary liver cancer. 
HCC is a major health problem worldwide, with an 
estimated incidence ranging between 500,000 and 
1,000,000 new cases annually. It is the 5th most common 
cancer in the world, and the 3rd most common cause 
of cancer-related death. For years, partial hepatectomy 
and liver transplantation have been considered as 
the main curative treatments. However, only 10 to 
20% of HCC is resectable. Anatomic location, size or 
number of lesions, inadequate liver remnant, or co-
morbid condition precludes surgery in the majority of 
patients. Orthotopic liver transplantation can cure some 
patients with poor liver function due to the underlying 
cirrhosis; however, only few are eligible due to 
the scarcity of donors.4 These devastating HCC 
problems are most likely due to failure in recognizing 
patients at risk (with hepatitis B and/or C), high 
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Figure.1 The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma5
PEI using pure ethanol. During a follow-up period of 
6–38 months, 19 (30%) subjects of the PAI group and 
21 (34%) subjects of the PEI group died (p = 0.704). 
The 1- and 3-year survival rates were 84% and 51% 
for the PAI group as well as 81% and 46% for the PEI 
group (p = 0.651). The corresponding tumor recurrence 
rates were 51% and 74% for the PAI group, and 54% 
and 64% for the PEI group (p = 0.787). PAI has 
the advantage of fewer treatment sessions in each 
treatment course. From the study, we conclude that PAI 
and PEI are equally effective in the treatment of HCC.6
 Sala et al, evaluated the early response of 282 
cirrhotic patients with unresectable early HCC who 
were treated with RFA, PAI, or PEI. Initial complete 
responses were achieved in 192 patients and were 
independently related to the size of the main tumor 
(p = 0.015) and tumor stage (p = 0.0001); (< 2 cm, 
96%; 2.1-3 cm, 78%; > 3 cm, 56%; 2-3 nodules, 
46%). At the end of follow-up,80 patients had 
sustained their complete response. The 1-, 3-, and 
5-year survival rates were 87%, 51%, and 27%, 
respectively. The independent predictors of survival 
were Child-Turcotte-Pugh (CTP) class (p = 0.0001) 
and initial complete response (p = 0.006). CTP class 
A patients with initial complete response achieved 
42% survival at 5 years; this figure increased to 63% 
in patients with 2 cm or smaller tumors. In conclusion, 
the study demonstrated that initial complete response to 
percutaneous ablation is associated with an improved 
survival in both CTP class A and B patients with 
nonsurgical HCC.7
Livraghi et al, compared the effectiveness of RFA 
with percutaneous ethanol injection in the treatment 
of small HCC. Eighty-six patients with 112 small 
(3-cm diameter) HCCs underwent RFA (42 patients 
with 52 tumors) or percutaneous ethanol injection 
(44 patients with 60 tumors). Therapeutic efficacy 
was evaluated with dual-phase spiral computed 
tomography performed at least 4 months after 
treatment. Complete necrosis was achieved in 47 
of 52 tumors with RFA (90%) and in 48 of 60 tumors 
with PEI (80%). One major complication (hemothorax 
that required drainage) and four minor complications 
(intraperitoneal bleeding, hemobilia, pleural effusion, 
cholecystitis) occurred in patients treated with RFA.8 
 Waki et al, evaluated the prognosis and associated 
factors in patients with small hepatocellular 
carcinoma (HCC; up to 3 nodules, each up to 3 cm in 
diameter) treated with percutaneous RFA as first-line 
treatment. Eighty-eight consecutive patients who had 
percutaneous RFA as first-line treatment were enrolled, 
among them 70 patients who had hypervascular HCC 
nodules were treated by a combination of transcatheter 
arterial chemoembolization and RFA therapy. RFA 
was repeated until an ablative margin was obtained. 
The rate of local tumor progression at 1 and 3 years 
was 4.8%, respectively. The rate of overall survival at 
3 and 5 years was 83.0% and 70.0%; while the rate of 
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disease-free survival at 3 and 5 years was 34.0% and 
24.0%, respectively. Overall survival of patients with 
early recurrence after RFA was significantly worse than 
that of patients with late recurrences. In conclusion, 
we consider that percutaneous RFA under the protocol 
reported here has the potential to provide local tumor 
control for small HCC. In addition to host factors, 
time interval from RFA to recurrence was an important 
determinant of prognosis.9 
Koda et al evaluated 73 nodules treated with 
percutaneous ethanol injection in 49 patients with 
small hepatocellular carcinoma. The clinicopathologic 
variables examined included age, gender, Child–
Pugh classification, number of tumors (single vs. 
multiple), tumor size, degree of tumor differentiation, 
ultrasonographic findings such as peripheral hypoechoic 
band (so-called ‘halo’), intra-tumoral echo pattern, 
tumor staining on enhanced computed tomography, 
combination therapy with transcatheter arterial 
embolization, and serum α-fetoprotein level. The local 
recurrence rates were 19%, 27%, 33%, 33%, and 33%, 
respectively, and the new nodular recurrence rates were 
19%, 51%, 74%, 83%, and 83%, respectively at 1, 2, 
3, 4, and 5 years after percutaneous ethanol injection 
therapy. The frequency of local recurrence was 
associated with the histological differentiation of more 
than moderately differentiated (p = 0.001), presence 
of a sonographic halo (p = 0.005), an intratumoral 
heterogeneous echo pattern (p = 0.001), and positive 
tumor staining on enhanced computed tomography 
(p = 0.01). This study showed that the presence of a halo 
and an intra-tumoral echo pattern on ultrasonography 
were useful predictors for local recurrence after PEI 
therapy for small hepatocellular carcinoma, and that 
a high serum a-fetoprotein level was associated with 
a higher frequency of new nodular recurrences.10
A prospective randomized control trial (RCT) 
was conducted by Ohnishi et al, to assess whether 
ultrasound-guided percutaneous acetic acid injection 
is superior to percutaneous ethanol injection in 
the treatment of small HCC. A total number of 
60 patients with one to four HCCs smaller than 
3 cm were enrolled in the trial. Thirty one and 
29 patients, respectively, were treated by PAI using 
50% acetic acid or by PEI using absolute ethanol. 
However, 8% of 38 tumors treated with PAI and 
37% of 35 tumors treated with percutaneous ethanol 
injection developed a local recurrence (p < 0.001), 
respectively. The first and second year survival rates 
were 100% and 92% in PAI and 83% and 63% in PEI 
(p = 0.0017). A multivariate analysis of prognostic 
factors revealed that treatment was an independent 
predictor of survival. The risk ratio of PAI versus 
PEI was 0.120 (p = 0.0050). In conclusion, the study 
indicates that PAI is superior to PEI in the treatment 
of small HCC.11
Lin et al, compared the clinical outcome of 
percutaneous RFA, conventional PEI, and higher-
dose PEI in treating HCC sized 4 cm or less. A total 
of 157 patients with 186 HCCs sized 4 cm or less 
were randomly assigned to 3 groups (52 patients in 
the conventional PEI group, 53 patients in the higher-
dose PEI group, and 52 patients in the RF group). 
Clinical outcomes in terms of complete tumor necrosis, 
overall survival, local tumor progression, additional 
new tumors, and cancer-free survival were compared 
across 3 groups. The rate of complete tumor necrosis 
was 88% in the conventional PEI group, 92% in 
the higher-dose PEI group, and 96% in the RF group. 
Significantly fewer sessions were required to achieve 
complete tumor necrosis in the RF group than in the 
other 2 groups (p < 0.01). The local tumor progression 
rate was lowest in the RF group (vs. the conventional 
PEI group, p = 0.012; vs. the higher-dose PEI group, 
p = 0.037). The overall survival rate was highest 
in the RF group (vs. the conventional PEI group, 
p = 0.014; vs. the higher-dose PEI group, p = 0.023). 
The cancer-free survival rate was highest in the RF 
group (vs. the conventional PEI group, p = 0.019; 
vs. the higher-dose PEI group, p = 0.024). From 
the above mentioned study, we concluded that RFA 
yields better clinical outcomes than conventional and 
higher-dose PEI in treating HCC sized 4 cm or less.12
Lin et al, compared the outcomes of RFTA, PEI, and 
PAI in the treatment of HCC. A total of 187 patients 
with HCCs of 3 cm or less were randomly assigned 
to RFTA (n = 62), PEI (n = 62), or PAI (n = 63). 
Tumor recurrence and survival rates were assessed. 
RFTA was superior to PEI and PAI with respect to 
local recurrence, overall survival, and cancer-free 
survival rates, but RFTA also caused more serious 
complications.13
 Shiina et al, compared RFA and PEI in RCT. 
The study included 232 patients with hepatocellular 
carcinoma who had 3 or fewer lesions, each 3 cm or 
less in diameter, and liver function of Child–Pugh class 
A or B. The primary end point was survival rate and the 
secondary end points were overall recurrence and local 
tumor progression. The number of treatment sessions 
was lesser (2.1 times vs. 6.4 times, respectively, p < 
0.0001) and the length of hospitalization was shorter 
(10.8 days vs. 26.1 days, respectively, p < 0.0001) in 
RFA than in PEI. Four year survival rate was 74% in 
RFA and 57% in PEI. RFA had 46% smaller risk of 
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death (p = 0.02), 43% smaller risk of overall recurrence 
(p = 0.0009), and 88% smaller risk of local tumor 
progression (p = 0.006) than PEI. The incidence 
of adverse events was not different between both 
therapies.14
A RCT, which was conducted by Brunello et al, 
compared PEI, the standard approach which has been 
used for many years to treat early non-surgical HCC 
in cirrhotic patients, and RFA, which has become an 
interesting alternative treatment. The trial evaluated 
139 cirrhosis patients in Child-Pugh classes A/B with 
1-3 nodes of HCC (diameter 15-30 mm), for a total of 
177 lesions. Patients were randomized to receive RFA 
(n = 70) or PEI (n = 69). The primary end-point was 
complete response (CR) 1 year after the percutaneous 
ablation of all HCC nodes identified at baseline. 
Secondary end-points were: early (30-50 days) CR, 
complications, survival and costs. The study result 
demonstrated that in the intention-to-treat analysis, 
1-year CR was achieved in 46/70 (65.7%) and in 25/69 
(36.2%) patients treated by RFA and PEI, respectively 
(p = 0.0005). For lesions > 20 mm in diameter, there was 
a larger CR rate in the RFA group (68.1% versus 26.3%). 
An early CR was obtained in 67/70 (95.7%) patients 
treated by RFA compared with 42/64 (65.6%) 
patients treated by PEI (p = 0.0001). Complications 
occurred in 10 and 12 patients treated by RFA and 
PEI, respectively. The overall survival rate was not 
significantly different in the RFA versus PEI arm. 
There was an incremental health-care cost for each 
additional patient successfully treated by RFA. Thus, 
we could conclude from this study that the 1-year 
CR rate after percutaneous treatment of early HCC is 
significantly better with RFA than with PEI; however, 
a clear survival advantage has not been revealed in 
cirrhotic patients.15
A meta-analysis evaluating five RCTs which 
included 701 patients demonstrated that RFA was 
superior to PEI in the treatment of small HCC with 
respect to overall survival, 1-, 2-, and 3-year survival 
rates, 1-, 2-, and 3-year cancer-free survival rates, 
as well as tumor response. Radio frequency showed 
a significantly smaller risk of local recurrence.16
In a meta-analysis study, Germani et al, compared 
treatment modalities of radiofrequency ablation, 
percutaneous alcohol and acetic acid injection by 
identifying comparison on survival rate, recurrence 
rate, tumor necrosis, and complications. RFA was 
superior to PEI for survival (p = 0.001), complete 
necrosis of tumor and local recurrence. For tumors 
> 2 cm, RFA was not significantly better than PEI. 
PAI did not differ significantly from PEI for survival 
(p = 0.18), and local recurrence; but it required 
less sessions. PAI had similar outcomes, except 
local recurrence, to RFA in the direct and indirect 
comparison. In conclusion, RFA seems to be a superior 
ablative therapy than PEI for HCC, particularly for 
tumors sized > 2 cm. PAI does not differ significantly 
from PEI for all the outcomes evaluated. RFA and 
PAI have similar survival rates. For tumors sized 
> 2 cm, the outcome benefits comparing RFA and PEI 
are similar. PAI needs re-evaluation versus both PEI 
and RFA for > 2 cm tumors.1
Yang et al, reported their retrospective study that 
evaluated effectiveness and safety of combined RFA 
and transcatheter arterial chemoembolization (TACE) 
treatment for recurrence of HCC post hepatectomy 
and compared them to single modality. A total of 
103 patients were included and divided into RFA group, 
TACE group and combination RFA and TACE group. 
Survival rate among combination RFA and TACE 
group had better result compared to single TACE 
modality (93.5 vs. 68.6%, p = 0.011). Recurrence rate 
and survival rate of 1-, 3-, and 5-years showed better 
result in combined RFA and TACE modality.17
Yuen et al, reported the effectiveness of TACE for 
early stage and unresectable HCC. A total of 96 Child-
Pugh A dan B HCC patients were included in the study.
The study suggested that TACE group have better 
survival rate than conservative therapy.18 Kirikoshi 
et al, reported the effects of TACE and combined 
therapies (TACE + PEI or TACE + RFA) on long-term 
survival rates, which were evaluated in 268 untreated 
HCC patients by using various statistical analyses. 
The cumulative survival rates in the TACE alone group 
were significantly superior to those in the palliative 
treatment group. Furthermore, the cumulative survival 
rates in the combined TACE + PEI/RFA group were 
significantly superior to those in the TACE alone group. 
When the comparison among the groups was restricted 
to patients with two or three tumors fulfilling the Milan 
criteria, significantly greater prolongation of survival 
was observed in the combined TACE + PEI/RFA group 
than in the PEI/RFA alone group. From this study, we 
conclude that the aforementioned treatment modalities 
yield greater improvements on the survival rate and 
survival duration as compared to palliative treatment 
in HCC patients. Moreover, in terms of the effect on 
survival period, combined TACE + PEI/RFA therapy 
was more effective than TACE monotherapy, and also 
more effective than PEI or RFA monotherapy in cases 
with multiple tumors fulfilling the Milan criteria.19
Percutaneous ablation under ultrasound guidance is 
currently the best therapy for early-stage HCC when 
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resection or liver transplantation is not possible. PEI 
with 95% alcohol and RFA result in complete necrosis 
of 95% of tumors sized < 2 cm, but only 50% when 
applied to tumors with 3–5 cm diameter, with survival 
rate of > 50% at 5 years. The best candidates are 
patients in Child-Pugh A stage with small HCC.1 
PEI is cheap, well-tolerated, simple to perform, and 
does not require a general anesthetic agents. Severe 
complications are infrequent at 0–2%, including 
seeding. There are some reasons for this. First, 
tumor necrosis is heterogeneous because ethanol 
does not diffuse uniformly within the nodule due to 
internal septa in 33% of nodules and encapsulation of 
the tumor.1 Second, ethanol is diluted by vascular 
washout; and third, the needle is not centrally 
positioned. 
Acetic acid used as a 50% solution is as cheap as 
alcohol. Moreover, it penetrates and destroys intra-
nodule septa due to its low pH and breaks down lipid 
and collagen fibers within intra-tumoral septa and 
capsules, which often contain cancer cells. PAI is 
performed as easily and safely as PEI, and it requires 
fewer treatment sessions.1,9
In order to decrease the risk of local recurrence, 
combined RFA and TACE treatment is recommendable; 
while to reduce late recurrence, the most effective 
therapy is decreasing relapse rate by using polyprenoic 
acid dan interferon.9
HCC resection could be performed safely in non-
cirrhotic patients. The best candidates to undergo 
resection is patients with solitary tumor, asymptomatic 
patients with good liver function (BCLC stage A1), and 
the 5-year survival rate is 70%.4
Neoplastic cells destruction could be achieved 
by using chemical substance (alcohol, acetic acid) 
or by modifying the temperature (radiofrequency, 
microwave, laser dan cryoablation). PEI is 
the procedure of choice for small tumor due to its 
high efficacy, minimal complications, and low cost. 
The mechanisms of PEI include dehydration, vascular 
occlusion, and fibrosis. Indication for PEI is small sized 
tumor (diameter < 5 cm), cirrhotic patients with Child-
Pugh A stage and unresectable tumor. The survival 
rate of patients who had PEI may increase up to 50%. 
RFA shows higher success rate than PEI; however, 
it has more complications and higher cost.
CONCLUSION
Early stage of HCC could be treated with curative 
treatment such as ablative therapies using PEI, PAI or 
RFA, and surgical resection or liver transplantation. 
RFA is more effective and safer than other modalities 
of local ablative therapies. RFA should be considered 
as the first-line treatment for patients with small 
HCC, who are not suitable for liver resection or liver 
transplantation. RFA should also be compared to 
transarterial embolization, which currently has been 
considered as the standard HCC therapy in some 
countries. It has been reported that the combination of 
RFA and embolization treatment may reduce the early 
and late recurrence rate. Since there are some risks of 
systematic error, including the risk of bias in trials and 
random errors due to small sample size of the trials 
and there are only a few number of trials; therefore, 
further trials are necessary. The data on small HCC are 
not conclusive and further RCTs should be performed 
comparing RFA, PEI and PAI.
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